The advent of combined neoadjuvant chemo-immune therapy has revolutionized the treatment of human epidermal growth factor receptor 2 (HER2)-amplified early-stage breast cancer, achieving pathologic complete response (pCR) rates of up to ≥ 50% [1]. The gene discussed is ERBB2; the disease is breast carcinoma.